Clinical Trial Update: Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating safety, tolerability, and pharmacokinetics of recombinant oncolytic vaccinia virus T601 alone or with oral 5-FC in patients with adva…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Solid Tumors

Drugs mentioned

• 5-fluorocytosine (5-fluorocytosine)
• T601 (recombinant oncolytic vaccinia virus) (recombinant oncolytic vaccinia virus T601)

Snippet

Sponsor: Tasly Tianjin Biopharmaceutical Co., Ltd. | Conditions: Advanced Malignant Solid Tumors | Phase 1, Phase 2 | Status: UNKNOWN